Human medicines European public assessment report (EPAR): Arixtra, fondaparinux sodium, Date of authorisation: 20/03/2002, Revision: 38, Status: Authorised

Veterinary medicines European public assessment report (EPAR): Varenzin, molidustat, Status: Authorised

Human medicines European public assessment report (EPAR): Heplisav B, hepatitis B surface antigen, Date of authorisation: 18/02/2021, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Biktarvy, bictegravir,emtricitabine,tenofovir alafenamide, Date of authorisation: 21/06/2018, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Erbitux, cetuximab, Date of authorisation: 29/06/2004, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Leflunomide Zentiva (previously Leflunomide Winthrop), leflunomide, Date of authorisation: 08/01/2010, Revision: 23, Status: Authorised

Emerging safety issues (ESI) contact points at the national competent authority (NCA) level

Human medicines European public assessment report (EPAR): Saphnelo, anifrolumab, Date of authorisation: 14/02/2022, Revision: 9, Status: Authorised

HMA-EMA Network Data Steering Group: membership list

HMA-EMA joint Network Data Steering Group meeting - 8 December 2025